IRLAB Presents Integrated Analysis of Mesdopetam Data at International Conference - Confirms Robust Efficacy Results in the Phase II Studies

GOTHENBURG, SE / ACCESS Newswire / June 16, 2026 / IRLAB Therapeutics AB ((STO:IRLAB-A)(FRA:6IRA), a company discovering and ...